Forget About Aurora Cannabis (TSX:ACB) Stock: This Proven Stock Is Heading Higher Right Now

Here’s why Biosyent Inc. (TSXV:RX) can be an excellent buy today for strong upside.

| More on:

Many investors get excited about the growth potential of marijuana stocks like Aurora Cannabis stock. Indeed, it has outperformed the market by appreciating about 40% in the last 12 months. However, the stock trades at a high price-to-sales ratio of close to 66. And it’s anyone’s guess if it can continue heading higher.

A new development for a proven growth stock

Here’s a growth stock that analysts believe has no downside risk (only upside potential). Biosyent (TSXV:RX) stock is trading about 5% higher after it announced a meaningful development for its business yesterday — Health Canada has approved a new drug for which Biosyent has exclusive distribution rights in Canada.

That is, the drug is new to Canada but not to other countries. It has been approved and marketed in Europe for more than 30 years, and it has been approved and marketed in other countries.

As the press release stated, “Tibella [is] indicated for the short-term treatment of vasomotor symptoms due to estrogen deficiency in postmenopausal women.”

Tibella complements and enhances Biosyent’s existing portfolio of women’s health products in the company’s Community and Women’s Health Business segment, which already consists of oral iron supplements (FeraMAX 150 and FeraMAX Powder), and sodium hyaluronate suppositories (RepaGyn and Proktis-M). IQVIA estimates that the sub-segment of the women’s health market that Tibella belongs in has a market value of about $200 million.

smiling female doctor

Biosyent’s track record

Biosyent is a proven growth stock. From 2013 to 2018, it has increased its revenue by 2.8 times (more than 22% per year) to $21.5 million and diluted earnings per share by three times (more than 60% per year). It has also maintained a high return on equity of 23% or greater. From 2014 to 2018, Biosyent’s EBITDA climbed more than 14% per year to $7.4 million.

While growing responsibly and profitability, Biosyent has kept the balance sheet clean with no debt and full of cash. The company’s cash and cash equivalents nearly quadrupled to $16.8 million from 2015 to 2018.

Upside potential

At $8 per share, as of writing, Biosyent trades at about 20.5 times 2018 earnings and a forward price-to-earnings ratio of about 19.1.

Buyers of Biosyent stock today can be well rewarded. Thomson Reuters has a 12-month mean target of $10 per share on the stock, which represents near-term upside potential of 25%.

Foolish takeaway

Biosyent has a primary focus in Canada and is a proven profitable business that sources, acquires or in-licenses innovative pharmaceutical products, which are proven safe and effective to improve the lives of patients.

Despite the pop, the healthcare stock still looks like a good value today and can be an excellent addition to a diversified portfolio with a focus on growth.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Kay Ng owns shares of Biosyent Inc. Biosyent is a recommendation of Hidden Gems Canada.

More on Stocks for Beginners

data analyze research
Stocks for Beginners

Top Canadian Stocks to Buy With $5,000 in 2025

Got $5,000 that you want to invest in some long-term stock holdings? These Canadian stocks could be the ideal fit…

Read more »

how to save money
Stocks for Beginners

Canada’s Biggest Winners in 2025? My Money’s on These 2 TSX Stocks

Here’s why I’m betting on these TSX stocks to be among Canada’s biggest winners in 2025.

Read more »

A plant grows from coins.
Stocks for Beginners

1 Canadian Stock Ready to Surge In 2025

First Quantum stock is one Canadian stock investors should seriously consider going into 2025, and hold on for life!

Read more »

Concept of multiple streams of income
Stocks for Beginners

The Smartest Dividend Stocks to Buy With $500 Right Now

The market is flush with great opportunities right now, and that includes some of the smartest dividend stocks every portfolio…

Read more »

customer uses bank ATM
Stocks for Beginners

A Dividend Giant I’d Buy Over TD Stock Right Now

While TD Bank recovers from a turbulent year, this dividend payer with a decent yield and lower payout ratio is…

Read more »

Start line on the highway
Stocks for Beginners

The Best Canadian Stocks to Buy and Hold Forever in a TFSA

Do you want some of the best Canadian stocks to buy? Here are three stellar options to kickstart your long-term…

Read more »

Blocks conceptualizing Canada's Tax Free Savings Account
Stocks for Beginners

Maximizing Returns Within Your 2025 TFSA Contribution Room

Maximize your 2025 TFSA contribution room by contributing the max amount and investing in solid stocks for the long term.

Read more »

coins jump into piggy bank
Dividend Stocks

A 10% Dividend Stock Paying Out Consistent Cash

This 10% dividend stock is one strong option for long-term income, but make sure you get a whole entire picture…

Read more »